Epigenic Therapeutics
Shanghai
About Epigenic Therapeutics
Epigenic Therapeutics is a biotechnology company focused on developing next-generation gene modulation therapies through the regulation of epigenetic mechanisms. The proprietary EPIREG™ technology platform allows for efficient, durable, and specific silencing of target genes via accurate DNA methylation and histone modification. In contrast to traditional gene-editing methods that depend on DNA cleavage, EPIREG™ presents a safer and groundbreaking therapeutic solution for individuals with chronic conditions, effectively addressing the safety issues linked to conventional gene editing. The company has pioneered two main technologies: epigenetic modulation and in-vivo lipid nanoparticle (LNP) delivery systems, which enhance the efficacy of gene therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $122.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2025)
- Website: epigenictx.com
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/epigenic-therapeutics-73433 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.